✓ AI summary
Summary of reporting by Fox News — Latest • • 1 min read
4 Wire-neutral provisional

✓ No loaded language, vague sourcing, or framing detected.

Experimental drug combination shows promise in treating advanced pancreatic cancer

Early clinical trial results indicate that the combination of the experimental drug daraxonrasib and standard chemotherapy is effective in treating advanced pancreatic cancer. The trial showed tumor shrinkage in 60.7% of patients, with a median progression-free survival of 12.8 months. Side effects were manageable for most participants. A larger Phase 3 trial is planned to further assess the treatment's benefits.

Companies
Revolution Medicines
People
Dr. Wungki Park Dr. Elena Garralda

A recent clinical trial has found that combining the experimental drug daraxonrasib with standard chemotherapy can effectively treat advanced pancreatic cancer. The study, presented at an international cancer conference, showed that 60.7% of patients experienced tumor shrinkage, and the median time before cancer worsened was 12.8 months. While side effects were reported, they were largely manageable. Researchers are now planning a larger trial to confirm these findings.

Key facts

  • The trial involved 61 patients with advanced pancreatic cancer.
  • Tumors shrank in 60.7% of patients, with complete disappearance in 8.2%.
  • Patients had a median progression-free survival of 12.8 months.
  • Side effects included rash, diarrhea, and fatigue, mostly manageable.
  • A larger Phase 3 trial, RASolute-303, is being launched.
Read the full story at Fox News — Latest

A short AI summary in our own words. The reporting belongs to Fox News — Latest; we don't reproduce it.

Annotating as

Notes are private: only you can see them.

No note attached

of yours on this article.

Original vs. Neutral

Original Headline

New drug combo shrinks tumors in most patients facing aggressive cancer type

Neutral Headline

Experimental drug combination shows promise in treating advanced pancreatic cancer